Aarti Drugs Limited
6,821words
5turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
Rs. 100
crore
Rs.
2,500
Rs. 2,000
Rs.
200
Rs. 200
Rs. 1,000 crore
100%
Rs. 100 crore
4,938
MT
35%
90%
Guidance — 4 items
Empowerment
opening
“• CRAMS industry has posted 48% CAGR between FY15-18 and expected to witness a strong growth over 25% over 2018-21 Formulations Biosimilars • Largest exporter of formulations in terms of volume, with 14% market share and 12th in terms of export value.”
Captive consumption
opening
“crores 14.0% 14.0% +10% 87 95 +33% 9.2% 63 7.6% 47 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Revenue -5% 2,533 2,403 EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) 12.7% 320 -5% 12.6% 303 6.8% 172 -2% 7.0% 168 s t h g i l i h g H 4 Q s t h g i l i h g H 5 2 Y F FY24 FY25 FY24 FY25 FY24 FY25 1.”
Captive consumption
opening
“EBITDA includes other income & excludes exceptional items Home 35 Segmental Break-up Q4FY25 82% 9% 6% 3% FY25 81% 11% 5% 3% API Speciality Chemicals Formulation Intermediates & Others API Speciality Chemicals Formulation Intermediates & Others Q4FY24 FY24 81% 11% 5% 3% 80% 13% 5% 2% API Speciality Chemicals Formulation Intermediates & Others API Formulation Speciality Chemicals Intermediates & Others 36 Consolidated Profit & Loss Statement Particulars (Rs.”
Captive consumption
opening
“Crores) Consolidated 2,718 2,500 2,533 2,403 442 2,159 341 308 321 303 280 205 166 172 168 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 EBITDA Margin (%) PAT Margin (%) 20.5% 13.0% 13.7% 12.7% 12.6% 11.3% 8.2% 6.1% 6.8% 7.0% FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Home 41 Strong Financial Performance EPS* (in Rs.) Net Worth (in Rs.”
Advertisement
Speaking time
1
1
1
1
1
Opening remarks
Empowerment
Free Government approved and certified vocational course training for women to generate employment. • Healthcare: Primary Healthcare Improvement around Infrastructure the Development and manufacturing facilities. • Gender Diversity: ~40% women staff at HO, contributing in various departments such as marketing, finance, procurement. At factory level, women are employed at QC QA, regulatory affairs, etc. departments. • trade Stakeholder Management: No unfair practices events in the last 5 years. stringent product quality control, strict QA and QC dept to ensure that product is at the mark of the quality as per various pharma copeial standards • The Board has an optimum combination of Executive and Non-Executive directors and gender diversification • Risk Management Governance • Occupational Healthy Policy • Policies governing related party transactions • In compliance with all regulatory requirement of the Audit Committee • Mechanism of periodic reporting to Stakeholders Relationship Com
Barriers
Presence in Highly Specialized API Segment 5. Robust Balance Sheet 2. Unique Competitive Position 4. Diversified product and client mix 3. Poised to overcome industry challenges High Entry Barriers : Presence in Highly Specialized API Segment Over a decade, API manufacturing has transitioned towards highly regulated, specialized business How API Manufacturing Has Evolved Impact Regulations ❑ Stringent pharmacopoeia standards ❑ Addition of elemental ❑ Tightened impurity profiling ❑ Rigorous carcinogenicity checks Cost Structure Higher capex requirements to adhere to ever rising quality, environmental & regulatory requirements High R&D costs Tightened Regulations Quality & Environmental Standards Higher Capex Requirements ❑ Lower Competitive Intensity: Various small-scale manufacturers have exited due to unviability of cost structure ❑ High Entry Barriers: High entry barriers for new entrants due to cost structure and compliance requirements ❑ API manufacturing has evolved from a commodi
Captive consumption
Rs. 300 crores Revenue Growth Higher Margins Higher RoCE Home 30 Product-wise Capex Plans Anti Diabetic ▪ CEP renewed by EDQM in 2022 ▪ Manufacturing over 1,000 TPM making it one of the largest metformin player ▪ Coming up with 1450 TPM capacity via brown field expansion in Q1FY24 ▪ Launch of Gliptins will further strengthen this therapeutic category. ▪ Exploring backward integration options. Antiprotozoal ▪ Further consolidating the position in Indian Market via brown field expansion by about 40% for couple of products ▪ Recently got approval to market the product in China ▪ Incremental expansions and downstream products improvement Vitamins / Anti- Inflammatory ▪ Multi-purpose facility under construction. Targeting highly regulated markets. ▪ Brown field expansion of its existing anti inflammatory products commissioned at the end of FY20 which will drive future growth in this therapeutic category ▪ Installed capacity will give revenues of around Rs. 50 crores / Rs. 35 crores per annu
Investor Relations Advisor
CIN: L37060MH1984PLC055433 CIN: U74140MH2010PTC204285 Mr. Rushikesh Deole Email: investorrelations@aartidrugs.com Contact no.: +91 22 24048199 Mr. Deven Dhruva E: deven.dhruva@sgapl.net T: +91 98333 73300 www.aartidrugs.co.in www.sgapl.net
Advertisement